Acid-responsive engineered bacteria with aberrant In-Situ anti-PD-1 expression for post-ablation immunotherapy of hepatocellular carcinoma
Authors:
Open Access
- 9 April 2025
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 186, 118046
Abstract
No abstract availableKeywords
Funding Information
- Basic and Applied Basic Research Foundation of Guangdong Province (2020A1515110654)
- National Natural Science Foundation of China (82202271)
- National Natural Science Foundation of China (82001930)
- National Natural Science Foundation of China (82172043)
- National Natural Science Foundation of China (82202273)
- National Natural Science Foundation of China (82001929)
This publication has 33 references indexed in Scilit:
- Hypoxia-targeting bacteria in cancer therapySeminars in Cancer Biology, 2024
- Eliminating METTL1‐mediated accumulation of PMN‐MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablationHepatology, 2022
- Bacteria and bacterial derivatives as delivery carriers for immunotherapyAdvanced Drug Delivery Reviews, 2022
- Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6‐Methyladenosine mRNA Methylation‐Dependent MechanismHepatology, 2021
- Chemotaxis-based self-accumulation of surface-engineered mitochondria for cancer therapeutic improvementNano Today, 2020
- Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2019
- Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent mannerCancer Letters, 2019
- Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapyEuropean Radiology, 2019
- Nanomaterial-Enabled Cancer TherapyMolecular Therapy, 2017
- Noninvasive Real-time Imaging of Tumors and Metastases Using Tumor-targeting Light-emitting Escherichia coliMolecular Imaging and Biology, 2007